New York Eye and Ear Infirmary
Adjust: Text Size Make Font Smaller Make Font Larger Print this Page: Normal Print Friendly Large Print Friendly Accessibility Info

Clinical Trials for Anterior Uveitis - EYEGATE study

Purpose

The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery System (EGDS) compared to prednisolone acetate ophthalmic suspension (1%) in patients with non-infectious anterior segment uveitis.

Eligibility

Dr. C. Michael Samson, Uveitis Specialist and Principal Investigator of this study can determine if you are eligible. 

You may qualify if you:

  • are Male or female, age 12 to 85 years with a diagnosis of non-infectious anterior segment uveitis defined as an anterior chamber cell count of ? 11 cells
  • Other protocol-defined inclusion/exclusion criteria may apply

This is a fully funded trial.  All research related procedures and medication will be at no cost to the patient.

Contact Information

To see if you qualify for the EYEGATE Study and to make an appointment, please call: Katy Tai, Clinical Research Manager at 212-979-4251.

 

Home > Current Research > Clinical Trials in Ophthalmology > Clinical Trials for Anterior Uveitis - EYEGATE study